Research Analysts’ Weekly Ratings Changes for Apellis Pharmaceuticals (APLS)

A number of firms have modified their ratings and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) recently:

• 11/9/2023 – Apellis Pharmaceuticals is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $74.00 price target on the stock.
• 11/2/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Raymond James from $92.00 to $93.00. They now have a “strong-buy” rating on the stock.
• 11/2/2023 – Apellis Pharmaceuticals is now covered by analysts at Mizuho. They set a “neutral” rating and a $42.00 price target on the stock.
• 11/1/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $60.00 to $63.00. They now have a “buy” rating on the stock.
• 10/12/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Bank of America Co. from $44.00 to $46.00. They now have a “neutral” rating on the stock.
• 10/6/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Raymond James from $89.00 to $92.00. They now have a “strong-buy” rating on the stock.
• 10/6/2023 – Apellis Pharmaceuticals was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $81.00 price target on the stock, up previously from $60.00.
• 10/6/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $54.00 to $70.00. They now have a “buy” rating on the stock.
• 10/6/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Bank of America Co. from $43.00 to $44.00.
• 9/26/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $82.00 price target on the stock.
• 9/20/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $82.00 price target on the stock.

Apellis Pharmaceuticals Price Performance

APLS traded up $1.21 during trading on Friday, reaching $49.10. The stock had a trading volume of 1,957,601 shares, compared to its average volume of 2,716,804. The business has a 50-day moving average of $44.98 and a 200-day moving average of $58.55. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.76 and a current ratio of 4.29. Apellis Pharmaceuticals, Inc. has a one year low of $19.83 and a one year high of $94.75. The stock has a market cap of $5.82 billion, a PE ratio of -9.35 and a beta of 0.97.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.29). Apellis Pharmaceuticals had a negative net margin of 222.16% and a negative return on equity of 209.10%. The business had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $99.05 million. During the same quarter in the previous year, the company earned ($1.75) earnings per share. The business’s quarterly revenue was up 400.5% on a year-over-year basis. As a group, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -4.59 EPS for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $47.27, for a total transaction of $567,240.00. Following the sale, the insider now directly owns 1,071,807 shares of the company’s stock, valued at approximately $50,664,316.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Cedric Francois sold 150,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $41.75, for a total transaction of $6,262,500.00. Following the completion of the transaction, the chief executive officer now directly owns 424,655 shares in the company, valued at $17,729,346.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $47.27, for a total transaction of $567,240.00. Following the transaction, the insider now owns 1,071,807 shares of the company’s stock, valued at $50,664,316.89. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 210,914 shares of company stock worth $8,938,011. Company insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in APLS. Jacobs Levy Equity Management Inc. purchased a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $4,166,000. Tudor Investment Corp Et Al boosted its holdings in Apellis Pharmaceuticals by 577.4% in the 3rd quarter. Tudor Investment Corp Et Al now owns 50,112 shares of the company’s stock worth $1,906,000 after buying an additional 42,714 shares during the period. Morgan Stanley boosted its holdings in Apellis Pharmaceuticals by 112.6% in the 3rd quarter. Morgan Stanley now owns 1,608,996 shares of the company’s stock worth $61,206,000 after buying an additional 852,331 shares during the period. Seven Eight Capital LP bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth $844,000. Finally, KPP Advisory Services LLC bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $362,000. 90.43% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).